Portal de informação sobre vários temas de gestão dos recursos públicos do Estado Português

Projeto Portugal 2030

A rigidez da matriz como um regulador principal de agressividade e resposta clínica do Cancro da Mama Triplo Negativo

Nesta página

Ficha de projeto

Nome do projeto

A rigidez da matriz como um regulador principal de agressividade e resposta clínica do Cancro da Mama Triplo Negativo

Valor de financiamento

212,5 mil €

Valor executado

0 €

Objetivo estratégico

+ Inteligente

Data de início prevista

01.09.2025

Data de conclusão prevista

30.08.2028

Objetivo específico

Reforçar a investigação, inovação e adoção de tecnologias avançadas.

Modalidade

Subvenção

Código de operação

COMPETE2030-FEDER-00667100

Sumário

In the clinic, it is well established that enhanced mammographic density is one of the strongest risk factors for breast cancer progression. In particular, premenopausal women with dense breasts are more likely to be diagnosed with triple-negative breast cancer (TNBC) than premenopausal women with non-dense breasts. Because TNBC is characterized by unfavorable outcome due to the combination of its metastatic propensity, chemo-refractory behavior and the general lack of effective targeted interventions, to effectively treat TNBC it is urgent to identify and target the mechanisms governing TNBC progression. MINNESOTA main goal is to identify a molecular mechanism underlying ECM mechanical properties driving TNBC invasiveness and therapeutical response. To that end, we set three specific aims: I. GENERATION OF GENETIC TOOLS TO MONITOR ESR DYNAMICS IN TNBC INVASIVE CELLS (Activity 1). To accurately assess ESR dynamics in vitro, state-of the art tools will be developed. These tools will be used throughout MINNESOTA. II. ASSESSMENT OF ESR DYNAMICS DOWNSTREAM OF TNBC DECELLULARIZED ECMS (dECMS) STIFFNESS (Activity2). Here, we will establish of ECM stiffness as a key regulator of ESR-driven cell invasion in patient-derived systems. We will start by bioengineering novel in tunable biomimetic dECM/alginate-based hydrogels. Using molecular tools (Activity 1), we aim to show for the first time that there is a correlation between the mechanical properties of the ECM and ESR dynamics. Particularly, we aim to show that ESR is differently regulated by stiff ECM. III. ESTABLISHMENT OF ECM STIFFNESS AS A KEY REGULATOR OF ESR DYNAMICS IN TNBC (Activity 3). In this activity, we aim to demonstrate that ESR supports ECM stiffness-triggered cell invasion of TNBC. Together with Activities 1 and 2, this Activity will unveil the molecular mechanism underlying ECM mechano-control over ESR during invasion of TNBC cells. IV. ASSESSMENT OF ECM-DEPENDENT ESR PATHWAY CLINICAL RELEVANCE IN TNBC (Activity 4). Here we aim to identify an association between the mechanical properties of the ECM, ESR dynamics regulation and response to taxanes and ESR inhibitors. By doing so, we aim to demonstrate the potential of ESR-regulators as potential tools to predict the responses to standard chemotherapy regimens to avoid invasion and metastasis formation; and/or targets for future clinical intervention. Altogether, these activities focused on studying ECM-dependent ESR regulation in TNBC invasion will set the stage for the development of an effective clinical intervention at an early stage of TNBC and is expected to contribute to halt TNBC progression. In the future, we plan on pushing forward this research by linking our discovery-phase findings to pre-clinical studies using transplantation-based mouse models. This project aims to directly contribute to decreasing the societal (and financial) costs of clinical management of co-morbidities associated with standard chemotherapy regimens. It will refine the criteria used to select patients for such regimens, decreasing the cost of drug administration in patients who will not benefit from it. Lastly, it will pave the way for future studies showing the potential of repurposing FDA-approved drugs available in off-patent libraries to target ESR regulators and treat early-stage and invasive TNBC cancers, which would reduce the financial investment on drug development, and new clinical trials.

Beneficiários

Beneficiários Principais

Candidaturas

Os Avisos de Candidatura proporcionam uma oportunidade para entidades públicas e privadas obterem financiamento para projetos que impulsionem a economia portuguesa. Cada aviso define um montante específico para investimento, disponibilizado aos beneficiários por meio de concurso ou convite.

Os projetos submetidos a concurso são avaliados por entidades específicas, com base em critérios de seleção estabelecidos nos avisos de candidatura. Quando aplicável, são atribuídas notas de avaliação aos projetos.

Nota final da candidatura

Nãoseaplica

Código do aviso

MPr-2023-12

Designação do aviso

SACCCT – Projetos de Investigação Científica e Desenvolvimento Tecnológico (IC&DT) - Operações Individuais e em Copromoção

Distribuição geográfica

Financiamento total do projeto

212,5 mil €

Percentagem de valor já executado para a realização de projetos

0 %,
Onde foi aplicado o dinheiro

Por concelho

1 concelho financiado .

  • Porto 212,46 mil € ,
Fonte AD&C
31.12.2025
Todos os temas
Transparência sem entrelinhas